SCHEMBL23501351

SCHEMBL23501351

CC(C)[Si](OCc1ccc([C@@H](CN2C(=O)c3ccccc3C2=O)C(=O)O)cc1)(C(C)C)C(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.44
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 2/20 0.38
PARP1 P09874 1/20 0.38
ALDH1A1 P00352 2/20 0.38
HTR1A P08908 1/20 0.38
ADRA1A P35348 1/20 0.38
POLB P06746 1/20 0.38
MMP2 P08253 1/20 0.37
MMP9 P14780 1/20 0.37
HDAC1 Q13547 3/20 0.37
HDAC7 Q8WUI4 3/20 0.37
CA12 O43570 1/20 0.37
CA9 Q16790 1/20 0.37
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL114458 1.00 MAPK1 (0.44) MAPK1CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL119084 0.90 ESR1 (0.42) MAPK1CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL23501359 0.89 MAPK1 (0.38) MAPK1KMT2AALDH1A1HTR1AADRA1A
SCHEMBL23501357 0.89 MAPK1 (0.38) MAPK1KMT2AALDH1A1HTR1AADRA1A
SCHEMBL23501237 0.87 TDP1 (0.41) MAPK1KMT2AHTR1AADRA1AMMP2
SCHEMBL111498 0.86 KMT2A (0.42) MAPK1KMT2AALDH1A1HTR1AADRA1A
SCHEMBL23501385 0.84 MAPK1 (0.43) MAPK1CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL23501458 0.79 ESR1 (0.38) CYP3A4CYP2D6CYP2C9CYP2C19KMT2A
SCHEMBL23501303 0.79 CYP3A4 (0.48) CYP3A4CYP2C19KMT2AALDH1A1HTR1A
SCHEMBL7746342 0.78 CA12 (0.53) MAPK1CYP3A4CYP2D6CYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112979675-B Small molecular sulfur-containing heterocyclic compound 维眸生物科技(上海)有限公司 2023-12-19 CN disclosed
US-20220332726-A1 NITROXIDE DERIVATIVE OF ROCK KINASE INHIBITOR VIVAVISION (SHANGHAI) LTD (CN) 2022-10-20 US disclosed
EP-3901156-A1 NITROOXYDERIVATIVE OF ROCK KINASE INHIBITOR Vivavision (Shanghai) Ltd (CN) 2021-10-27 EP disclosed
CN-111217834-B Nitroxide derivatives of ROCK kinase inhibitors 维眸生物科技(上海)有限公司 2021-10-26 CN disclosed
CN-112979675-A Small-molecule sulfur-containing heterocyclic compound 维眸生物科技(上海)有限公司 2021-06-18 CN disclosed
WO-2021115495-A1 SMALL-MOLECULE SULFUR-CONTAINING HETEROCYCLIC COMPOUND 维眸生物科技(上海)有限公司 2021-06-17 WO disclosed
CN-111217834-A Nitroxide derivatives of ROCK kinase inhibitors 维眸生物科技(上海)有限公司 2020-06-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332726-A1 NITROXIDE DERIVATIVE OF ROCK KINASE INHIBITOR ROCK1, NOS1, ROCK2 MAPK1 47/4885CYP3A4 629/4885CYP2D6 785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.